Center-Authored Papers

Filters: Author is Kenoyer, Aimee L  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
V
O'Steen S, Green DJ, Gopal AK, Orozko JJ, Kenoyer AL, Lin Y, Wilber SD, Hamlin DK, Fisher DR, Hylarides MD et al..  2017.  Venetoclax Synergizes with Radiotherapy for Treatment of B cell Lymphomas.. Cancer research. 77(14):3885-3893. Abstract
Q
Miller BW, Frost SHL, Frayo SL, Kenoyer AL, Santos E, Jones JC, Green DJ, Hamlin DK, Wilbur SD, Fisher DR et al..  2015.  Quantitative single-particle digital autoradiography with α-particle emitters for targeted radionuclide therapy using the iQID camera.. Medical physics. 42(7):4094. Abstract
P
Park SI, Shenoi J, Frayo SM, Hamlin DK, Lin Y, Wilbur SD, Stayton PS, Orgun N, Hylarides M, Buchegger F et al..  2011.  Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphoma.. Clinical cancer research : an official journal of the American Association for Cancer Research. 17(23):7373-82. Abstract
Green DJ, Orgun NN, Jones JC, Hylarides MD, Pagel JM, Hamlin DK, Wilbur DS, Lin Y, Fisher DR, Kenoyer AL et al..  2014.  A Preclinical Model of CD38-Pretargeted Radioimmunotherapy for Plasma Cell Malignancies.. Cancer research. 74(4):1179-89. Abstract
C
Park SI, Shenoi J, Pagel JM, Hamlin DK, Wilbur SD, Orgun N, Kenoyer AL, Frayo S, Axtman A, Bäck T et al..  2010.  Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease.. Blood. 116(20):4231-9. Abstract
Green DJ, Frayo SL, Lin Y, Hamlin DK, Fisher DR, Frost SHL, Kenoyer AL, Hylarides MD, Gopal AK, Gooley TA et al..  2016.  Comparative analysis of bispecific antibody and streptavidin-targeted radioimmunotherapy for B cell cancers.. Cancer research. Abstract
B
Nakamae H, Wilbur SD, Hamlin DK, Thakar MS, Santos EB, Fisher DR, Kenoyer AL, Pagel JM, Press OW, Storb R et al..  2009.  Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211.. Cancer research. 69(6):2408-15. Abstract
A
Green DJ, Shadman M, Jones JC, Frayo SL, Kenoyer AL, Hylarides MD, Hamlin DK, Wilbur SD, Balkan ER, Lin Y et al..  2015.  Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model.. Blood. 125(13):2111-9. Abstract
Pagel JM, Kenoyer AL, Bäck T, Hamlin DK, Wilbur SD, Fisher DR, Park SI, Frayo S, Axtman A, Orgun N et al..  2011.  Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model.. Blood. 118(3):703-11. Abstract
Frost SHL, Miller BW, Bäck TA, Santos EB, Hamlin DK, Knoblaugh SE, Frayo SL, Kenoyer AL, Storb R, Press OW et al..  2015.  Alpha Imaging Confirmed Efficient Targeting of CD45-Positive Cells after Astatine-211 (211At)-Radioimmunotherapy for Hematopoietic Cell Transplantation.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 56(11):1766-73. Abstract